Diabetes & Metabolic Care
Comprehensive diabetes management across Iraq.
Diabetes is one of Iraq's most significant chronic-disease challenges. Al Sumo distributes and scientifically promotes comprehensive diabetes-care portfolios, from established oral therapies to modern treatment classes.
Market outlook
Iraq's insulin market potential alone is estimated at more than USD 200 million (IQVIA / MOH 2024), with chronic-disease management among the market's key growth drivers.
Partner opportunities
Insulin and modern diabetes portfolios are a declared strategic priority. Partners gain nationwide chronic-care channel access and cold-chain reliability.
Current portfolio categories
- Oral antidiabetics
- Insulin therapies
- Metabolic care
- Patient-support-oriented supplements
Scientific & commercial support
- Scientific detailing by trained medical representatives
- KOL engagement and advisory boards
- Regulatory registration and lifecycle management
- GDP-aligned warehousing and cold chain
- Nationwide distribution across 18 governorates
- Tender participation and hospital access
The information on this website is intended for general corporate and educational purposes. It does not replace professional medical advice, diagnosis, or treatment.